CX3CL1 Signaling in the Tumor Microenvironment

Melissa J Conroy1, Joanne Lysaght2

  • 1Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin, St James's Hospital, Dublin 8, Ireland. MECONROY@tcd.ie.

Insights

Fractalkine (CX3CL1) and its receptor CX3CR1 have dual roles in inflammation and anti-tumor immunity. Understanding their complex functions is crucial for developing targeted cancer therapies.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Fractalkine (CX3CL1) is a chemokine with a single receptor, CX3CR1, mediating diverse cellular effects.
  • Its function varies from adhesion molecule to chemotactic cytokine, influencing immune cell survival and retention.
  • The CX3CL1:CX3CR1 axis is implicated in inflammatory disorders and cancer immunity.

Purpose of the Study:

  • To review the structure, function, and biology of CX3CL1.
  • To address the diverse biological effects of CX3CL1 in the immune system and tumor microenvironment.
  • To explore the potential of the CX3CL1 pathway as a therapeutic target in cancer.

Main Methods:

  • Literature review of studies on CX3CL1 and CX3CR1.
  • Analysis of CX3CL1's role in inflammatory and anti-viral/anti-tumor immunity.
  • Examination of conflicting reports on CX3CL1's pro-tumorigenic and anti-tumorigenic functions.

Main Results:

  • CX3CL1 exhibits context-dependent roles, acting as an adhesion molecule or chemoattractant.
  • It plays a key role in maintaining effector memory cytotoxic T cells, crucial for anti-viral and anti-tumor immunity.
  • CX3CL1 is reported as a TIL-recruiting chemokine and positive prognostic factor in some cancers, yet also linked to pro-tumorigenic and pro-metastatic effects in others.

Conclusions:

  • The CX3CL1:CX3CR1 pathway presents a complex therapeutic target due to its dual roles in inflammation and immunity.
  • Further mechanistic studies are required to fully elucidate CX3CL1's multifaceted functions in cancer.
  • Appreciating all CX3CL1 interactions is vital for its potential as a cancer therapeutic target.